A distal enhancer controls cytokine-dependent human cPLA2α gene expression

Area of Science:

• Molecular Biology
• Cellular Signaling
• Inflammation Research

Background:

• Group IVA cytosolic phospholipase A2 (cPLA2α) regulates arachidonic acid production, impacting inflammatory and anti-inflammatory pathways.
• Dysregulation of cPLA2α is implicated in various diseases, including inflammation and cancer.
• Transcriptional regulation of cPLA2α has primarily focused on proximal promoter regions, leaving distal regulatory mechanisms unexplored.

Purpose of the Study:

• To identify and characterize novel distal regulatory elements controlling cPLA2α gene transcription.
• To elucidate the molecular mechanisms underlying interleukin (IL)-1β-mediated transcriptional activation of cPLA2α.
• To investigate the roles of transcription factors c-Jun and C/EBPβ in cPLA2α gene regulation.

Main Methods:

• Identification of a distal enhancer using DNase I hypersensitivity assays.
• Chromatin immunoprecipitation (ChIP) to assess protein-DNA interactions.
• Gene knockdown and knockout studies to evaluate the function of c-Jun.
• Overexpression analyses to confirm regulatory roles.
• Analysis of c-Jun phosphorylation and C/EBPβ association with the enhancer.

Main Results:

• A novel 5' distal enhancer containing a conserved AP-1 site was identified, mediating IL-1β-induced cPLA2α transcription.
• c-Jun plays a dual role, acting as both a negative and positive regulator of cPLA2α expression.
• Transcriptional activation involves c-Jun phosphorylation and enhanced association of C/EBPβ with the distal enhancer.
• C/EBPβ binding to the enhancer does not require a canonical DNA binding site.

Conclusions:

• This study reveals a previously unknown distal enhancer that plays a critical role in the transcriptional regulation of cPLA2α.
• The findings highlight the complex interplay of transcription factors, including c-Jun and C/EBPβ, in controlling cPLA2α expression.
• Understanding this novel regulatory mechanism offers potential therapeutic targets for diseases involving aberrant eicosanoid metabolism and inflammation.